Summary
The pharmacokinetics of piretanide was studied in 10 patients with chronic renal failure. After administration of a high oral dose (12 to 192 mg) of piretanide the kinetics behaved according to an open 2-compartment model. The elimination constant in the first phase (α) ranged from 0.385 to 0.756 h−1 and in the second phase (β) from 0.079 to 0.274 h−1. The corresponding elimination half-lives ranged from 55 to 108 min (t1/2 α) and from 152 to 524 min (t1/2 β). Only an average of 2.8% of the orally administered drug was recovered in 24 h urines. Nevertheless, a good correlation was found between urinary recovery or renal clearance of the drug and residual renal function. The elimination of piretanide by non-renal mechanisms appeared to be increased when renal function was greatly diminished.
Similar content being viewed by others
References
Marone C, Reubi FC (1980) Effects of a new diuretic (piretanide) compared with furosemide on renal diluting and concentrating mechanisms in patients with the nephrotic syndrome. Eur J Clin Pharmacol 17: 165–171
Marone C, Reubi FC, Lahn W (1984) The short-term effects of the loop diuretic piretanide in patients with renal insufficiency. A comparison with furosemide. Eur J Clin Pharmacol 26: 413–418
Berg KJ, Walstad RA, Bergh K (1983) The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. Br J Clin Pharmacol 15: 347–353
Brazier JL, Pozet N, Faucon G, Traeger J, Hadj-Haissa A (1982) Kinetics of a high dose of piretanide in renal failure. Eur J Clin Pharmacol 21: 307–310
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41
Heptner W, Baudner S, Dagrosa EE, Hellstern C, Irmisch R, Strecker H, Wissmann H A radioimmunoassay to measure piretanide in human serum and urine (abstract). J Immunoassay (in press)
Lawrence JR, Ansari AF, Elliott HL, Sumner DJ, Brunton GF, Whiting B, Withesmith R (1978) Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther 23: 558–565
Elliott HL, Ansari AF, Campbell BC, Lawrence JR (1982) Protein binding of piretanide in normal and uraemic serum. Eur J Clin Pharmacol 21: 311–313
Cutler RE, Forrey AW, Christopher TG, Kimpel BM (1974) Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 15: 588–596
Huang CM, Atkinson AJ Jr, Levin M, Levin NW, Quintalla A (1974) Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 16: 659–666
Beermann B, Dalén E, Lindström B (1977) Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22: 70–78
Marcantonio LA, Auld WHR, Murdoch WR, Purohit R, Skellern GG, Howes CA (1983) The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. Br J Clin Pharmacol 15: 245–252
Berg KJ, Tromsdal A, Wideroe TE (1976) Diuretic action of bumetanide in advanced chronic renal insufficiency. Eur J Clin Pharmacol 9: 265–275
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marone, C., Reubi, F.C., Perisic, M. et al. Pharmacokinetics of high doses of piretanide in moderate to severe renal failure. Eur J Clin Pharmacol 27, 589–593 (1984). https://doi.org/10.1007/BF00556897
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00556897